Novartis (NVS) -12.7% premarket to <meta name=

39.56 on Tuesday Sept 8 — Phase III HARBOR of del-desiran (from 2B Avidity buyout) misses primary vHOT endpoint in myotonic dystrophy type 1; third trial setback in a week" /> 39.56 on Tuesday Sept 8 — Phase III HARBOR of del-desiran (from 2B Avidity buyout) misses primary vHOT endpoint in myotonic dystrophy type 1; third trial setback in a week" />

Stock/TLDR — What Just Moved Markets: Earnings, Fed, M&A, MoversA high-volume feed of market-moving releases — quarterly earnings, FOMC decisions, M&A, regulatory actions, big single-name moves, macro prints, commodities and crypto — refreshed every 12 hours. Each release is explained in plain English so you actually understand what just happened and which tickers it touches.This site uses JavaScript to render the interactive feed. Enable JavaScript to use it.Stock/TLDR is not investment advice. Verify everything against primary sources before trading.